Amended Statement of Ownership (sc 13g/a)
09 December 2017 - 12:54AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE 13G/A
Under the Securities
Exchange Act of 1934
(Amendment
No. 1)*
ATARA BIOTHERAPEUTICS,
INC.
(Name of Issuer)
Common Stock,
$0.0001 par value per share
(Title of Class
of Securities)
046513107
(CUSIP Number)
December 5,
2017
(Date of Event
Which Requires Filing of this Statement)
Check the appropriate
box to designate the rule pursuant to which this Schedule is filed:
|
*
|
The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in
a prior cover page.
|
The
information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 046513107
1)
|
Names of reporting persons.
CELGENE CORPORATION
|
2)
|
Check the appropriate box if a member of a group (see instructions)
(a)
¨
(b)
¨
|
3)
|
SEC use only
|
4)
|
Citizenship or place of organization
Delaware, U.S.A.
|
Number of
shares
beneficially
owned by
each
reporting
person
with:
|
5)
|
Sole voting power
1,154,540
|
6)
|
Shared voting power
0
|
7)
|
Sole dispositive power
1,154,540
|
8)
|
Shared dispositive power
0
|
9)
|
Aggregate amount beneficially owned by each reporting person
1,154,540
|
10)
|
Check
if the aggregate amount in Row (9) excludes certain shares (see instructions)
¨
|
11)
|
Percent of class represented by amount in Item 9
3.8% (1)
|
12)
|
Type of reporting person (see instructions)
CO
|
|
(1)
|
The
percentage ownership is based upon 30,595,866 shares of Common Stock outstanding as of October 31, 2017 as reported in the
Issuer’s Quarterly Report filed with the Securities and Exchange Commission on November 9, 2017.
|
ITEM 1.
Atara Biotherapeutics, Inc.
|
(B)
|
ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICE:
|
611 Gateway Blvd., Suite 900,
South San Francisco, California 94080
ITEM 2.
|
(A)
|
NAME OF PERSONS FILING:
|
Celgene Corporation
|
(B)
|
ADDRESS OF PRINCIPAL BUSINESS OFFICE OR IF NONE, RESIDENCE:
|
86 Morris Avenue, Summit, New Jersey
07901
Delaware, U.S.A.
|
(D)
|
TITLE OF CLASS OF SECURITIES:
|
Common Stock, $0.0001 par value
046513107
|
ITEM 3.
|
STATEMENT FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B)
OR (C)
|
Not applicable.
(a), (b) and (c) —
The information contained on the cover page to this Schedule 13G/A is incorporated herein by reference.
|
ITEM 5.
|
OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
|
If this statement is being filed to
report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of
the class of securities, check the following
x
.
|
ITEM 6.
|
OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER
PERSON
|
Not applicable.
ITEM 7.
IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY
Not applicable.
|
ITEM 8.
|
IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
|
Not applicable.
|
ITEM 9.
|
NOTICE OF DISSOLUTION OF GROUP
|
Not applicable.
ITEM 10. CERTIFICATION.
Not applicable.
Signature
After reasonable inquiry and to the
best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: December 8, 2017
|
CELGENE CORPORATION
|
|
|
|
|
By:
|
|
/s/ Thomas M. Perone
|
|
|
|
Thomas M. Perone
|
|
|
|
Assistant Secretary
|
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2024 to May 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From May 2023 to May 2024